The Role of Genetic Factors in the Development of Arterial Hypertension in the Kazakh Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-30

Study Completion Date

2023-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a GWAS study that aims to identify possible candidate genes associate to arterial hypertension by exploring single nucleotide polymorphism (SNP) in a group of arterial hypertension, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with arterial hypertension

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of Genetic Factors in the Development of Myocardial Infarction in the Kazakh Population

NCT05090618

Heart Attack

COMPLETED

The Role of Genetic Factors in the Development of Idiopathic Osteoarthritis of the Knee in the Kazakh Population

NCT05095142

Idiopathic Osteoarthritis

COMPLETED

Gene-Environment Interactions in Complex Disease

NCT00064506

Cardiovascular Diseases Heart Diseases Atherosclerosis +1 more

COMPLETED

Genome-wide Association Study of Development of Collateral Circulation for Patients With Coronary or Peripheral Artery Disease

NCT05043948

Coronary Disease Peripheral Arterial Disease Collateral Circulation, Any Site

RECRUITING

Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults

NCT02496858

Coronary Artery Disease Percutaneous Coronary Intervention

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group:

Patients with arterial hypertension

DNA analysis

Intervention Type GENETIC

GWAS

Control group

Patients without arterial hypertension

DNA analysis

Intervention Type GENETIC

GWAS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DNA analysis

GWAS

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persons with confirmed arterial hypertension;
* The age of patients is from 18 to 55 years old inclusive;
* Persons of Kazakh nationality, whose paternal and maternal grandparents identify themselves as Kazakhs;
* Persons who are able and willing to provide written informed consent;
* Persons capable and willing to comply with the research protocol;

Exclusion Criteria

* Persons under 18 and over 55;
* Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
* Pregnant or lactating women;
* Tuberculosis of any localization in the active phase and in history;
* Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
* Severe and decompensated course of endocrine diseases;
* Autoimmune diseases;
* Systemic diseases;
* Cancer.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No